Abstract
Risk classification of early-stage breast cancer patients by gene expression profiling can result in substantial drug cost savings. Economic analyses suggest that appropriate use of clinically validated molecular diagnostics offers the potential for cost savings and improved patient quality of life.
Original language | English |
---|---|
Pages (from-to) | 9-12; discussion 17-18 |
Journal | Managed care (Langhorne, Pa.) |
Volume | 17 |
Issue number | 7 Suppl 7 |
State | Published - Jul 2008 |
ASJC Scopus subject areas
- Health Policy
- Public Health, Environmental and Occupational Health